Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this large multicenter, randomized, double-blinded, controlled clinical study
is to investigate the efficacy and safety of Cyclosporin A for primary Sjogren's syndrome
associated pneumonitis(pSS-IP), which has important implications for the establishment of
standardized diagnosis and treatment of pSS-IP.